0
Letters |

Obesity and Survival Among Patients With Pancreatic Cancer

Mark R. Goldstein, MD; Luca Mascitelli, MD; Francesca Pezzetta, MD
JAMA. 2009;302(16):1752-1753. doi:10.1001/jama.2009.1510
Text Size: A A A
Published online

To the Editor: The case-control study by Dr Li and colleagues1 found a significant association between obesity and overall survival among patients with pancreatic cancer. The article did not discuss chronic medication use by the participants, and it is possible that insulin, insulin secretagogues, metformin, and statin therapy might have confounded this relationship.

Obese individuals are more likely to be treated chronically with antidiabetic drugs and statins because of their metabolic abnormalities. Although in vitro data suggest that statins might decrease pancreatic cancer cell invasion and metastasis,2 clinical trial data suggest that chronic statin therapy may increase cancer incidence, particularly in elderly persons.3 This might result from a statin-induced increase in regulatory T-cell numbers and functionality, leading to an impairment of host antitumor response and increased cancer promotion.4 Additionally, in a recent case-control study, insulin or insulin secretagogue therapy was associated with an increased risk of pancreatic cancer, whereas metformin was associated with a decreased risk.5

It may be informative if the authors have additional information on medication use among the patients in their study.

AUTHOR INFORMATION

Financial Disclosures: None reported.

REFERENCES

Li D, Morris JS, Liu J,  et al.  Body mass index and risk, age of onset, and survival in patients with pancreatic cancer.  JAMA. 2009;301(24):2553-2562
PubMedCrossRef
Kusama T, Mukai M, Iwasaki T,  et al.  3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.  Gastroenterology. 2002;122(2):308-317
PubMedCrossRef
Shepherd J, Blauw GJ, Murphy MB,  et al; PROSPER study group; PROspective Study of Pravastatin in the Elderly at Risk.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.  Lancet. 2002;360(9346):1623-1630
PubMedCrossRef
Goldstein MR, Mascitelli L, Pezzetta F. Do statins prevent or promote cancer?  Curr Oncol. 2008;15(2):76-77
PubMedCrossRef
Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer.  Gastroenterology. 2009;137(2):482-488
PubMedCrossRef

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Li D, Morris JS, Liu J,  et al.  Body mass index and risk, age of onset, and survival in patients with pancreatic cancer.  JAMA. 2009;301(24):2553-2562
PubMedCrossRef
Kusama T, Mukai M, Iwasaki T,  et al.  3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.  Gastroenterology. 2002;122(2):308-317
PubMedCrossRef
Shepherd J, Blauw GJ, Murphy MB,  et al; PROSPER study group; PROspective Study of Pravastatin in the Elderly at Risk.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.  Lancet. 2002;360(9346):1623-1630
PubMedCrossRef
Goldstein MR, Mascitelli L, Pezzetta F. Do statins prevent or promote cancer?  Curr Oncol. 2008;15(2):76-77
PubMedCrossRef
Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer.  Gastroenterology. 2009;137(2):482-488
PubMedCrossRef
October 28, 2009
Donghui Li, PhD; Manal M. Hassan, MD, PhD; James L. Abbruzzese, MD
JAMA. 2009;302(16):1752-1753.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.